Federal Register Notice: FDA has determined the regulatory review period for Chiron Corp.’s Kepivance (palifermin) is 3,303 days for extending a patent which claims the human biological product. The agency recently approved for marketing the human biological product Kepivance to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. To view this notice, click here.